Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HUMAM W FARAH

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1306880141
CMS profile
13577
Location
HANNIBAL, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$198,041.77

288 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 6 of 6; records 251–288 of 288 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HUMAM W FARAH

NPI 1306880141 · CMS profile ID 13577

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

HANNIBAL, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–288 of 288 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306880141?year=2023&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HUMAM W FARAH, NPI 1306880141, CMS profile ID 13577. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–288 of 288 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306880141?year=2023&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). HUMAM W FARAH, NPI 1306880141, CMS profile ID 13577. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–288 of 288 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306880141?year=2023&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
HUMAM W FARAH, NPI 1306880141, CMS profile ID 13577, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–288 of 288 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1306880141?year=2023&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

288 matching records · $198,041.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 288 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–288 of 288.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $950.0002/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014141589 CMS
Takeda Pharmaceuticals U.S.A., Inc. $835.7402/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385137 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,214.9902/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385139 CMS
Takeda Pharmaceuticals U.S.A., Inc. $351.1402/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385141 CMS
Takeda Pharmaceuticals U.S.A., Inc. $204.0602/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385143 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.3602/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385145 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,049.9902/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385131 CMS
Takeda Pharmaceuticals U.S.A., Inc. $90.8602/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385133 CMS
Takeda Pharmaceuticals U.S.A., Inc. $277.1402/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385135 CMS
Novartis Pharmaceuticals Corporation $16.5702/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991740009 CMS
AstraZeneca Pharmaceuticals LP $21.5302/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016084391 CMS
Takeda Pharmaceuticals U.S.A., Inc. $911.5002/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385115 CMS
Takeda Pharmaceuticals U.S.A., Inc. $85.1502/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385117 CMS
Takeda Pharmaceuticals U.S.A., Inc. $85.1502/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385119 CMS
Takeda Pharmaceuticals U.S.A., Inc. $36.0002/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385121 CMS
Takeda Pharmaceuticals U.S.A., Inc. $40.1402/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385123 CMS
Takeda Pharmaceuticals U.S.A., Inc. $67.5802/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385125 CMS
Takeda Pharmaceuticals U.S.A., Inc. $49.1402/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385127 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.2102/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385129 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.3302/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385113 CMS
Mylan Specialty L.P. $4.1701/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039064297 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,658.0001/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385109 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,658.0001/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385111 CMS
Harmony Biosciences LLC $2.3001/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013630919 CMS
Harmony Biosciences LLC $15.6301/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013630949 CMS
Amgen Inc. $23.5701/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020589113 CMS
Harmony Biosciences LLC $1.6101/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013630915 CMS
Harmony Biosciences LLC $19.4501/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013630961 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.5201/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385107 CMS
Takeda Pharmaceuticals U.S.A., Inc. $455.1301/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385105 CMS
Takeda Pharmaceuticals U.S.A., Inc. $235.9501/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385099 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,075.0201/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385101 CMS
Takeda Pharmaceuticals U.S.A., Inc. $100.3901/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385103 CMS
Takeda Pharmaceuticals U.S.A., Inc. $253.4901/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385095 CMS
Takeda Pharmaceuticals U.S.A., Inc. $110.3701/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385097 CMS
Takeda Pharmaceuticals U.S.A., Inc. $232.7101/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385093 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.4501/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055385091 CMS
AstraZeneca Pharmaceuticals LP $950.0001/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015624793 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $118,282.80 199
PY2020 $42,654.49 88
PY2021 $86,725.20 153
PY2022 $155,529.72 228
PY2023 $198,041.77 288
PY2024 $97,931.15 261
PY2025 $140,947.82 250

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $448,936.97 95
PY2024 Principal investigator $373,396.41 90
PY2023 Principal investigator $339,821.24 65
PY2022 Principal investigator $338,256.33 25
PY2021 Recipient $150.00 1
PY2021 Principal investigator $108,561.52 5
PY2020 Principal investigator $235,197.34 25
PY2019 Principal investigator $57,964.10 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

95 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $1,032.80 12/22/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226124635
Principal investigator 1 Genentech, Inc. $1,801.00 12/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211601555
Principal investigator 1 Genentech, Inc. $1,313.00 12/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211601614
Principal investigator 1 Genentech, Inc. $1,313.00 12/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211601628
Principal investigator 1 Genentech, Inc. $450.00 12/16/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211611859
Principal investigator 1 Genentech, Inc. $375.00 12/16/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211611863
Principal investigator 1 Genentech, Inc. $458.00 12/16/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211611868
Principal investigator 1 Genentech, Inc. $675.00 12/11/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211611842
Principal investigator 1 Genentech, Inc. $396.00 12/11/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211611846
Principal investigator 1 Genentech, Inc. $375.00 12/11/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211611850
Principal investigator 1 Genentech, Inc. $585.00 12/11/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211611854
Principal investigator 1 SANOFI US SERVICES INC. $2,300.00 12/08/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226124639
Principal investigator 1 United Therapeutics Corporation $350.00 12/02/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385675
Principal investigator 1 Genentech, Inc. $788.00 11/21/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211601511
Principal investigator 1 Genentech, Inc. $77.00 11/19/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211601535
Principal investigator 1 Genentech, Inc. $5,866.00 11/18/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611932
Principal investigator 1 Genentech, Inc. $2,600.00 11/12/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211611907
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,313.00 11/07/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM, INC
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185554783
Principal investigator 1 United Therapeutics Corporation $600.00 11/07/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385687
Principal investigator 1 United Therapeutics Corporation $800.00 11/07/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385689
Principal investigator 1 United Therapeutics Corporation $1,100.00 11/07/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385691
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 11/04/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226124631
Principal investigator 1 SANOFI US SERVICES INC. $18,608.00 10/27/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226124629
Principal investigator 1 Genentech, Inc. $2,763.00 10/21/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211611830
Principal investigator 1 Genentech, Inc. $1,500.00 10/14/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611813
Principal investigator 1 Genentech, Inc. $3,153.80 10/14/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611818
Principal investigator 1 Genentech, Inc. $1,008.00 10/14/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611822
Principal investigator 1 Genentech, Inc. $2,556.00 10/14/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611833
Principal investigator 1 Genentech, Inc. $1,000.00 10/14/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611838
Principal investigator 1 SANOFI US SERVICES INC. $3,881.70 10/14/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226124625
Principal investigator 1 Genentech, Inc. $3,000.00 10/08/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211611903
Principal investigator 1 SANOFI US SERVICES INC. $1,400.00 10/06/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226124615
Principal investigator 1 SANOFI US SERVICES INC. $1,050.00 10/06/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226124619
Principal investigator 1 United Therapeutics Corporation $3,217.65 10/06/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385707
Principal investigator 1 Genentech, Inc. $1,926.00 10/02/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211611826
Principal investigator 1 United Therapeutics Corporation $448.00 09/25/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385685
Principal investigator 1 United Therapeutics Corporation $2,571.00 09/25/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385697
Principal investigator 1 United Therapeutics Corporation $3,019.00 09/25/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385701
Principal investigator 1 United Therapeutics Corporation $3,019.00 09/25/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385705
Principal investigator 1 United Therapeutics Corporation $13,300.00 09/25/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385717
Principal investigator 1 United Therapeutics Corporation $13,300.00 09/25/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385719
Principal investigator 1 AstraZeneca Pharmaceuticals LP $427.92 09/24/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH, INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185554785
Principal investigator 1 SANOFI US SERVICES INC. $1,655.10 09/15/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226124610
Principal investigator 1 Genentech, Inc. $7,395.00 09/11/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611919
Principal investigator 1 Genentech, Inc. $1,926.00 09/02/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211611924
Principal investigator 1 Genentech, Inc. $10,567.00 08/21/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611915
Principal investigator 1 Merck Sharp & Dohme LLC $1,031.00 08/14/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
A Test-Negative Case-Control Study to Evaluate the Effectiveness of V116 Against Pneumococcal Pneumonia in Older Adults No dispute reported 06/30/2026 1232940097
Principal investigator 1 Genentech, Inc. $18,190.00 08/05/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211611928
Principal investigator 1 United Therapeutics Corporation $448.00 07/31/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385683
Principal investigator 1 United Therapeutics Corporation $3,019.00 07/31/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385703
Principal investigator 1 United Therapeutics Corporation $13,300.00 07/31/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385721
Principal investigator 1 SANOFI US SERVICES INC. $600.00 07/21/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226124607
Principal investigator 1 SANOFI US SERVICES INC. $4,205.70 07/14/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226124603
Principal investigator 1 United Therapeutics Corporation $6,435.30 07/04/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385713
Principal investigator 1 Genentech, Inc. $3,258.00 07/02/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211611898
Principal investigator 1 Genentech, Inc. $1,584.00 06/04/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211611894
Principal investigator 1 Genentech, Inc. $1,180.00 05/28/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211601324
Principal investigator 1 Genentech, Inc. $325.00 05/28/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211601343
Principal investigator 1 Genentech, Inc. $2,100.00 05/28/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211601355
Principal investigator 1 Genentech, Inc. $309.00 05/27/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611787
Principal investigator 1 Genentech, Inc. $30,734.00 05/27/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611790
Principal investigator 1 Genentech, Inc. $750.00 05/27/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611799
Principal investigator 1 United Therapeutics Corporation $448.00 05/15/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385679
Principal investigator 1 United Therapeutics Corporation $2,571.00 05/15/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385695
Principal investigator 1 United Therapeutics Corporation $3,019.00 05/15/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385699
Principal investigator 1 Merck Sharp & Dohme LLC $6,847.00 05/14/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
A Test-Negative Case-Control Study to Evaluate the Effectiveness of V116 Against Pneumococcal Pneumonia in Older Adults No dispute reported 06/30/2026 1232940095
Principal investigator 1 Genentech, Inc. $1,000.00 05/13/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611804
Principal investigator 1 Genentech, Inc. $23,024.00 05/06/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211611808
Principal investigator 1 SANOFI US SERVICES INC. $4,887.00 05/05/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226124594
Principal investigator 1 Genentech, Inc. $9,032.00 04/22/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE S
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211611795
Principal investigator 1 SANOFI US SERVICES INC. $18,600.00 04/14/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226124599
Principal investigator 1 Genentech, Inc. $2,758.00 04/09/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211601360
Principal investigator 1 SANOFI US SERVICES INC. $1,550.00 04/07/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226124587
Principal investigator 1 SANOFI US SERVICES INC. $7,426.10 04/07/2025 Non-covered Recipient Entity
Vantage Clinical Trials Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226128570
Principal investigator 1 United Therapeutics Corporation $400.00 04/07/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385677
Principal investigator 1 United Therapeutics Corporation $448.00 04/07/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385681
Principal investigator 1 United Therapeutics Corporation $2,571.00 04/07/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385693
Principal investigator 1 United Therapeutics Corporation $6,038.00 04/07/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385711
Principal investigator 1 United Therapeutics Corporation $26,600.00 04/07/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385723
Principal investigator 1 United Therapeutics Corporation $8,341.95 04/04/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385715
Principal investigator 1 SANOFI US SERVICES INC. $3,463.00 04/02/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226124582
Principal investigator 1 Genentech, Inc. $792.00 03/21/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211611883
Principal investigator 1 SANOFI US SERVICES INC. $20,000.00 03/17/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226124572
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $5,465.30 03/12/2025 Non-covered Recipient Entity
BLESSING CORPORATE SERVICES INC. DBA BLESSING HEALTH SYSTEM
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype No dispute reported 06/30/2026 1214125502
Principal investigator 1 Genentech, Inc. $1,905.00 03/03/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211601236
Principal investigator 1 Genentech, Inc. $1,584.00 02/28/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211611878
Principal investigator 1 SANOFI US SERVICES INC. $3,948.00 02/18/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226124577
Principal investigator 1 Genentech, Inc. $792.00 02/12/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211611887
Principal investigator 1 Genentech, Inc. $36,333.00 02/06/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211611911
Principal investigator 1 Genentech, Inc. $792.00 01/31/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211611873
Principal investigator 1 SANOFI US SERVICES INC. $2,688.00 01/21/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226124568
Principal investigator 1 Genentech, Inc. $1,300.00 01/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211601191
Principal investigator 1 Genentech, Inc. $1,180.00 01/17/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211601268
Principal investigator 1 Genentech, Inc. $2,376.00 01/13/2025 Non-covered Recipient Entity
HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211611890
Principal investigator 1 United Therapeutics Corporation $4,528.65 01/09/2025 Non-covered Recipient Entity
Hannibal Regional Healthcare System
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242385709